More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a prostate cancer diagnosis.
The reason is that the traditional prostate cancer screening test – a blood test to measure prostate specific antigen, or PSA – does not give doctors a complete picture.
A new test developed at the University of Michigan Comprehensive Cancer Center improves upon PSA. It adds two more markers that might indicate prostate cancer. Studies have shown the urine-based test, called Mi-Prostate Score, is far more accurate than PSA alone.
Mi-Prostate Score, or MiPS, is available to anyone, but requires a request from a doctor.
Take the next step:
- Read about the research study behind this test
- Check out frequently asked questions
- Direct your doctor to order the MiPS test
- Talk to a Cancer AnswerLine nurse: 800-865-1125
Learn more about prostate cancer detection and prevention
- The PSA and beyond: An update on prostate cancer biomarkers
- Prostate cancer risk is elevated for men with Lynch syndrome
- Gathering your family history
The Department of Urology is made up of a multidisciplinary group of physicians and scientists with a common purpose: curing urologic diseases. Because of the depth of our clinical care and research programs, our team provides significant contributions to the understanding of both adult and pediatrc urologic diseases and cancers.
The University of Michigan Comprehensive Cancer Center’s 1,000 doctors, nurses, care givers and researchers are united by one thought: to deliver the highest quality, compassionate care while working to conquer cancer through innovation and collaboration. The center is among the top-ranked national cancer programs, and #1 in Michigan for cancer patient care. Seventeen multidisciplinary clinics offer one-stop access to teams of specialists for personalized treatment plans, part of the ideal patient care experience. Patients also benefit through access to promising new cancer therapies.